Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-05-21
Item 7.01
The disclosure reveals material clinical development information about NanoViricides' drug candidates, including that NV-387 is "now entering Phase II clinical trial against Mpox in DRC" and that the company has developed an oral formulation of remdesivir encapsulated in NV-387 nanoviricide micelles with demonstrated efficacy in animal models. The company also states it has "a clinical site in DRC for treatment of Mpox patients." This represents significant clinical progress and pipeline advancement that would affect a reasonable investor's assessment of the company's development stage and commercial prospects, but does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation).
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-05-21
Item 8.01
Rigetti's wholly-owned subsidiary entered into a non-binding Letter of Intent with the U.S. Department of Commerce for a $100 million CHIPS and Science Act award over three years, contingent on negotiating definitive agreements and involving issuance of common stock to the Department at a discounted price.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces completion of an FDA meeting regarding zervimesine for dementia with Lewy bodies patients with psychosis. This represents a material regulatory milestone for a clinical-stage biopharmaceutical company, but does not fit neatly into more specific categories (not an earnings release, M&A activity, or litigation). FDA meeting outcomes can materially affect development timelines and investor expectations for drug candidates.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The Company disclosed its net asset value per Class I Share of $29.23 as of April 30, 2026 (aggregate NAV ~$1.582 billion) and reported that its ongoing private offering has raised $1.667 billion of a $5.0 billion target.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The filing discloses the closing of a subscription offering in connection with the conversion of Pioneer Federal Savings and Loan Association to a stock bank and the establishment of PSB Financial as its holding company, with the Company's common stock commencing quotation on OTCQB under symbol "PNSB" on May 22, 2026. While this represents a significant corporate restructuring and capital event, it does not fit neatly into the more specific event categories (it is not a traditional M&A activity, dilutive issuance, or earnings release), making "other_material" the most appropriate classification for this material conversion and initial public quotation event.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The disclosure announces EXIM Board approval of a $2.9 billion senior secured long-term loan to support development of the Stibnite Gold Project. While this is a material financing event that would significantly affect investor assessment of the company's capital structure and project funding, it does not fit cleanly into the standard M&A taxonomy categories. The event is neither a traditional acquisition/disposition nor a debt covenant breach or going-concern disclosure, making "other_material" the most appropriate classification for this major project financing approval.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The Company entered into a new $1.2 billion Five-Year Revolving Credit Agreement on May 15, 2026, replacing a prior $1.0 billion facility. While this represents a material refinancing and increase in available liquidity, it does not fit neatly into the more specific event categories (ma_activity applies to acquisitions/dispositions, not credit facility amendments; covenant_breach applies to violations, not new covenant establishment). The disclosure is material to investors as it affects the Company's financial flexibility and capital structure, but the event is best classified as other_material given the absence of a dedicated taxonomy entry for credit facility amendments or refinancings.
View raw filing on EDGAR →
8-K
Other material
confidence 85%
filed 2026-05-21
Item 8.01
Adagio Medical submitted a Premarket Approval (PMA) application to the FDA for its vCLAS® Ventricular Ablation System, a significant regulatory milestone for a medical device company. This event is material to investors as FDA approval is a critical path to commercialization and revenue generation, but it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, litigation, or other defined types). The submission of a major regulatory application represents a material corporate development warranting disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 8.01
The filing discloses entry into material financing arrangements: an Indenture Supplement dated May 28, 2026 for issuance of "Offered Notes" and a Risk Retention Agreement among First National Bank of Omaha, First National Funding LLC, and First National Master Note Trust. While this involves debt issuance and securitization activity, the Item 8.01 classification and absence of explicit M&A language make it distinct from standard ma_activity. The disclosure of note offerings and related indenture supplements would materially affect investor assessment of the registrant's capital structure and financing activities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces initial clinical trial data (Duravelo-2) for a candidate therapeutic in metastatic urothelial cancer presented at ASCO. For a clinical-stage or development-focused biopharmaceutical company, positive or significant clinical data announcements are material to investors assessing pipeline progress and regulatory prospects. However, this does not fit neatly into the standard taxonomy categories (not earnings, M&A, impairment, litigation, etc.), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 5.03
GCI Liberty, Inc. changed its corporate name to Liberty Capital Corporation effective May 21, 2026, through amendments to its Articles of Incorporation and Bylaws. The name change does not affect security holders' rights, trading symbols (GLIBA, GLIBB, GLIBK), or CUSIP numbers.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-21
Item 8.01
Black Diamond Therapeutics announced positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, demonstrating a preliminary median progression-free survival of 15.2 months, an objective response rate of 60%, and no new safety signals.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 3.03
CarParts.com implemented a 1-for-10 reverse stock split, effective May 25, 2026, following stockholder approval on May 11, 2026. The reverse split modifies the company's capital structure, affects share count and trading mechanics, and results in a new CUSIP number.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 5.03
Insulet Corp amended and restated its Bylaws to establish exclusive forum selection provisions for derivative actions, fiduciary duty claims, and Securities Act claims, affecting shareholders' litigation rights and corporate governance.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-21
Item 8.01
Beta Bionics announced an updated commercialization timeline for its lead product candidate, Mint ACE insulin pump, expecting full commercialization by end of Q2 2027 subject to FDA clearance. This material product development milestone affects investor assessment of the company's near-term revenue prospects and regulatory progress.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 7.01
This Item 7.01 disclosure presents BREIT's Q1 2026 quarterly update, including performance metrics (+2.0% net return), portfolio composition, and strategic positioning. While it contains performance data and forward-looking commentary on real estate markets and BREIT's investment strategy, it does not constitute a formal earnings release (no complete financial statements or standardized earnings metrics), nor does it fit cleanly into other specific event categories. The disclosure is material to investors as it provides substantive updates on fund performance, portfolio allocation, and capital deployment, but the format and content are more consistent with a general investor update than a traditional earnings announcement.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 7.01
The FDA reclassified non-invasive bone growth stimulators from Class III to Class II, triggering CMS reimbursement changes that reduce Medicare reimbursement by approximately 10% for HCPCS codes E0747, E0748, and E0760. This regulatory action materially impacts Orthofix's financial outlook, forcing the company to lower full-year 2026 net sales guidance to $838–$848 million and adjusted EBITDA to $90–$93 million, and to withdraw its three-year financial targets. While this is a material event affecting investor assessment, it does not fit neatly into the more specific categories (it is neither a restatement, impairment, covenant breach, nor litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 5.03
The company adopted an Amended and Restated Memorandum and Articles of Association in connection with its IPO on May 19, 2026, establishing the company's post-IPO governance structure and shareholder rights.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 8.01
The company reset its dividend policy, reducing the annual dividend rate to $0.50 per share and declaring a quarterly dividend of $0.1250 per share, representing a significant change to shareholder return policy.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 1.01
GATX Corporation amended its Five Year Credit Agreement on May 21, 2026, extending the termination date by one year to May 21, 2031 and reducing borrowing margins and facility fees. This material refinancing/restructuring of existing debt terms does not constitute an acquisition, disposition, or change of control.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 1.01
Victory Capital entered into a Seventh Amendment to its Credit Agreement on May 18, 2026, refinancing existing term loans with repriced term loans at lower interest rates (SOFR plus 1.75% or alternate base rate plus 0.75%), materially affecting the company's debt structure and cost of capital.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
Alphabet closed a ¥576.9 billion (~$3.8 billion USD equivalent) underwritten public offering of Japanese yen-denominated senior notes across seven tranches with maturities from 2029 to 2066. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the standard M&A, dilutive equity issuance, or other specific event categories—it is a debt financing activity disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
Charles Schwab issued $2.25 billion in aggregate principal amount of senior notes ($1 billion at 4.744% due 2030 and $1.25 billion at 5.493% due 2037) with net proceeds of approximately $2.236 million. This is a material debt issuance that does not fit the dilutive_issuance category (which applies to equity securities) and is not a covenant breach, restatement, or other more specific event type. The disclosure of a substantial debt offering is material to investors assessing the registrant's capital structure and financial position.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 2.03
EagleRock Land assumed a $263.3 million Predecessor Credit Facility (maturing July 3, 2027) and entered into a new $200 million revolving Credit Facility with JPMorgan Chase in connection with its IPO closing, materially altering the company's capital structure and leverage position.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
FMC announced the pricing of a $1.2 billion offering of Senior Secured Notes due 2031. While this is a material debt issuance that would affect investor assessment of the company's capital structure and financial position, it does not fit cleanly into the taxonomy's more specific categories (ma_activity applies to acquisitions/dispositions/mergers, not debt offerings; dilutive_issuance applies to equity securities). The disclosure is material but best classified as other_material given the debt financing nature.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-21
Item 8.01
Olema Pharmaceuticals announced preliminary Phase 1 clinical data for OP-3136, a KAT6 inhibitor, demonstrating favorable safety, tolerability, and early efficacy signals including tumor shrinkage in 13 of 19 patients and 3 partial responses with no dose-limiting toxicities. This clinical progress is material to investors' assessment of the company's pipeline and development prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces an option agreement with Hangzhou DAC Biotechnology providing access to a linker-payload (CPT113) for up to five additional ADC programs, which expands the Company's pipeline. While this represents a material strategic development for a biotech company's product pipeline, it does not fit cleanly into the more specific event categories (not an M&A transaction, not an earnings release, not an executive change, and not a financial impairment or covenant breach). The pipeline expansion through a licensing/option agreement is material to investors assessing the company's future prospects but is best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
The filing discloses that unit holders may elect to separately trade Class A ordinary shares and warrants commencing May 21, 2026, with separated securities trading under distinct NYSE symbols (KPET and KPET.WS). This is a structural change affecting the trading and composition of the company's securities, which would materially affect investor options and the total mix of information available. However, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or other defined event type), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-05-21
Item 1.01
Amanat Acquisition Corp. consummated its IPO on May 18, 2026, raising $75 million in gross proceeds from the sale of 7.5 million Class A shares at $10 per share, and entered into multiple ancillary agreements including underwriting, trust, registration rights, and indemnification agreements governing the offering and post-IPO operations.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-05-21
Item 5.03
The Company's articles of incorporation were amended and filed with the Cayman Islands General Registry on May 18, 2026 in connection with the IPO, with substantive terms incorporated by reference to the Registration Statement, though the specific governance changes are not detailed in the 8-K excerpt.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
Blackstone Secured Lending Fund disclosed the issuance and closing of $650 million in aggregate principal amount of 5.900% notes due 2031 on May 21, 2026, pursuant to an Eleventh Supplemental Indenture. While this is a material debt issuance that would affect a reasonable investor's assessment of the Fund's capital structure and financial obligations, it does not fit neatly into the more specific event categories (e.g., it is not a restatement, covenant breach, or going-concern disclosure). The disclosure focuses on the terms, covenants, and mechanics of the debt offering rather than a discrete triggering event like a breach or impairment.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces board approval of an increase and extension of the Company's stock repurchase program. While share repurchase programs can signal management confidence in valuation and affect capital allocation, this announcement does not fit cleanly into the more specific event categories (it is not an earnings release, executive change, M&A activity, impairment, or other defined material event). The materiality to investors lies in the capital allocation decision and potential impact on share count and EPS, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
Hoth Therapeutics announced a material name change to Rocket One, Inc. and a fundamental strategic pivot from therapeutics to artificial intelligence infrastructure, semiconductors, and ultra-low-power AI computing.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
This disclosure describes the completion of a SPAC IPO and related capital-raising activities, including the initial IPO of 16 million units generating $160 million in gross proceeds, private placement of 5.2 million warrants, and subsequent exercise of the underwriter's over-allotment option for 1.5 million additional units generating $15 million. While the IPO itself is a material capital event, it does not fit cleanly into the "earnings_release" category (which typically applies to periodic financial results) or "dilutive_issuance" (which focuses on unregistered equity sales to raise cash in distressed contexts). The disclosure is primarily a post-closing announcement of a completed IPO and related warrant issuances, which is material to investors but lacks a more specific event-type match.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces that the Company's 11% Series B Cumulative Convertible Preferred Stock commenced trading on Nasdaq Global Market under symbol "FBYDP" on May 21, 2026. While this represents a significant capital structure event and public market listing of a security class, it does not fit cleanly into the standard taxonomy categories (not a dilutive issuance of common equity, not M&A activity, not a routine administrative matter). The event is material to investors as it affects the Company's capital structure and introduces a new publicly-traded security class.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 7.01
The Company disclosed ongoing progress toward a Business Combination and indicated it hopes to disclose more details in the near future, reflecting material M&A activity for the SPAC.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 7.01
WhiteFiber announced entry into a five-year, $160+ million AI compute infrastructure contract with an investment-grade technology customer in France, including secured data center capacity and binding project-level financing expected to close in June 2026. While this represents a material commercial development that would affect a reasonable investor's assessment of the company's growth prospects and revenue pipeline, it does not fit cleanly into the standard M&A taxonomy (no acquisition, merger, or change of control) and is disclosed under Item 7.01 (Regulation FD Disclosure) rather than the dedicated Item 1.01 for material agreements. The contract's materiality—representing substantial contracted revenue and strategic positioning in AI infrastructure—warrants classification as a material event, but the absence of a more specific category makes "other_material" the most appropriate choice.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure reports the issuance of $15 million in consolidated obligation bonds (CUSIP 3130BAU47, maturing 5/27/2031, 4.875% coupon) by the Federal Home Loan Bank of San Francisco on trade date 5/19/2026. While Item 2.03 is nominally about "creation of a direct financial obligation," the filing itself states that "consolidated obligations issuance is material to the Bank" and the Bank has not made materiality judgments on particular obligations. This is a routine debt issuance disclosure for a government-sponsored enterprise (FHLB), not a covenant breach, going-concern issue, or other acute financial stress signal. The event is material to investors as it affects the Bank's capital structure and leverage, but does not fit neatly into more specific event categories (e.g., it is not a breach, impairment, or M&A activity), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure describes the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While the filing creates direct financial obligations through debt issuance, the prose is primarily explanatory and regulatory in nature, describing the general framework and mechanics of consolidated obligations rather than disclosing a specific new obligation event. The filing explicitly states "we have not made a judgment as to the materiality of any particular consolidated obligation or obligations," suggesting this is a routine periodic disclosure of debt issuance activity rather than a discrete material event. This does not fit cleanly into the more specific event types (covenant_breach, going_concern, etc.) and is best classified as other_material given the inherent materiality of debt issuance to a financial institution.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $890 million across eight separate securities issued on trade dates 05/18/2026 and 05/19/2026. While Item 2.03 is the designated item for direct financial obligations, the taxonomy lacks a specific "debt_issuance" category. The disclosure is material to investors as it represents significant new debt obligations for the FHLBank, though the filing itself notes the FHLBank has not made a materiality judgment on individual obligations. This is classified as "other_material" rather than a more specific event type because debt issuance activity, while routine for a Federal Home Loan Bank, does not fit cleanly into the provided taxonomy categories.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure reports the issuance of Consolidated Bonds ($19.5M and $15.5M par amounts) by the Federal Home Loan Bank of Cincinnati on trade dates 5/19/2026. While Item 2.03 is technically designated for "Creation of a Direct Financial Obligation," the filing itself explicitly states "although Consolidated Obligations issuance is material to the FHLB, we have not made a judgment as to the materiality of any particular Consolidated Obligation or Obligations." The disclosure does not fit cleanly into the covenant_breach taxonomy (no breach alleged) and represents routine debt issuance rather than a discrete material event like M&A, impairment, or executive change. The materiality assertion combined with the routine nature of debt issuance for a Federal Home Loan Bank suggests classification as other_material rather than a more specific event type.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—describing the mechanics of consolidated obligation issuance, the joint and several liability structure, and referencing Schedule A for specific debt instruments. This does not fit cleanly into covenant_breach (no violation alleged) or the more specific debt-related categories, making other_material the most appropriate classification for this regulatory debt disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure reports the issuance of consolidated obligations (bonds and discount notes) totaling approximately $781 million across multiple tranches with varying maturities and coupon rates. While Item 2.03 is technically designated for "Creation of a Direct Financial Obligation," the filing itself explicitly states "although consolidated obligations issuance is material to the Bank, we have not made a judgment as to the materiality of any particular consolidated obligation or obligations." The disclosure is routine for a Federal Home Loan Bank's ordinary course debt issuance operations, not a discrete material event like a covenant breach or going-concern issue. This is best classified as other_material rather than covenant_breach, as it represents standard debt capital-raising activity rather than a triggering financial stress event.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure reports the issuance of consolidated obligations (bonds and discount notes) totaling approximately $293 million across seven separate debt securities issued in May 2026. While Item 2.03 typically signals covenant_breach or direct financial obligations arising from adverse events, this filing discloses routine debt issuances by a Federal Home Loan Bank to fund operations—a standard capital markets activity. The disclosure is material to investors as it reflects the Bank's funding activities and debt structure, but does not fit the specific event types (covenant_breach, ma_activity, or dilutive_issuance) as cleanly as other_material, since these are consolidated obligations jointly backed by all 11 FHLBanks rather than a discrete triggering event or breach.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $505 million across five separate debt securities issued in May 2026. While Item 2.03 is technically designed for covenant_breach events, the filing's explicit focus on debt issuance—a material financing activity for a Federal Home Loan Bank—does not fit cleanly into the covenant_breach category. The disclosure is material to investors assessing the Bank's capital structure and funding activities, but the event itself (routine debt issuance by a government-sponsored enterprise) lacks the distress signal of a covenant violation or the transformative nature of M&A activity.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 2.03
The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds totaling $260 million with maturities ranging from one to four years. While Item 2.03 typically covers debt covenant breaches or off-balance sheet arrangements, this disclosure is fundamentally about the creation of direct financial obligations through bond issuances. The materiality is clear given the substantial principal amounts and multi-year maturities, but the event does not fit cleanly into the covenant_breach category (no breach is disclosed) and lacks the specific characteristics of other defined event types, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling approximately $2.37 billion across multiple tranches with varying maturities (ranging from 8/20/2026 to 5/26/2056) and rate structures. While Item 2.03 typically signals covenant_breach or material debt obligations, the filing itself explicitly states "the Bank has not made a judgment as to the materiality of these consolidated obligation bonds," and the disclosure is routine debt issuance activity for a Federal Home Loan Bank. The event is material to investors as a significant funding activity, but does not fit cleanly into the more specific event categories (no covenant breach, no going concern, no impairment), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The disclosure announces a quarterly cash dividend declaration of $0.975 per share, which is a material capital allocation decision affecting shareholder returns. While dividend declarations are routine for established dividend-paying companies, this represents a material event to investors assessing the company's financial health and shareholder value distribution. It does not fit the more specific event categories (earnings, M&A, executive changes, etc.) and is best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 7.01
BioCardia disclosed positive preliminary clinical trial results for CardiAMP Cell Therapy presented at a major medical conference (Euro PCR), showing safety (no major adverse cardiac events) and efficacy outcomes (179-second improvement in exercise tolerance, 82% reduction in angina episodes at six months through two-year follow-up). While this is clinical trial data rather than financial results or a traditional earnings release, the positive efficacy and safety findings for a lead therapeutic candidate are material to investors' assessment of the company's pipeline and commercial prospects. This does not fit neatly into the earnings_release category (which typically refers to financial results) but represents a material clinical milestone disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The filing discloses a special cash distribution of $0.12 per common unit (approximately $4.6 million) approved by the General Partner in addition to scheduled monthly distributions. While routine distributions may not be material, the special distribution—triggered by the Partnership's debt-free status, elevated market prices, and operational cash flow—represents a material capital allocation decision that would affect a reasonable investor's assessment of the Partnership's financial position and distribution policy. This does not fit neatly into the standard taxonomy categories and is best classified as other_material.
View raw filing on EDGAR →